ArticleIrish journal of medical science2026
Clinical significance of lncRNA EGFR-AS1 in gestational diabetes mellitus and its regulation of endothelial cell function.
Article in Irish journal of medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGestational diabetes mellitus (GDM) causes APOs. The diagnostic OGTT has a lag, and the role of lncRNA EGFR-AS1 in GDM has potential.
aimsThis study evaluated the potential of EGFR-AS1 for the GDM clinical application and explored the role of the EGFR-AS1/miR-142-5p/ROCK2 axis in placental endothelial injury.
methodsSerum EGFR-AS1, miR-142-5p and ROCK2 levels were detected via qPCR in 135 GDM patients and 110 healthy pregnant women. The clinic value of EGFR-AS1 was analyzed using ROC and logistic regression. A high glucose (HG)-induced model was established, in which EGFR-AS1 was silenced alone or co-silenced with miR-142-5p. The regulatory mechanism of EGFR-AS1/miR-142-5p/ROCK2 axis on placental endothelial injury was then analyzed via CCK-8, ELISA, qPCR, and WB.
resultsIn GDM patients, serum EGFR-AS1 and ROCK2 were elevated, whereas miR-142-5p was reduced. Serum EGFR-AS1 showed high diagnostic efficiency for GDM and acted as an independent predictor of APOs occurrence. Silencing EGFR-AS1 reversed HG-induced HPVECs injury-evidenced by inhibited inflammatory factor release, balanced oxidative stress, up-regulated pro-angiogenic factors mRNA expression, and down-regulated proteins expression related to apoptosis and endothelial injury. Dual-luciferase reporter assays confirmed binding between EGFR-AS1 and miR-142-5p, as well as between miR-142-5p and ROCK2. Notably, co-inhibiting EGFR-AS1 and miR-142-5p abolished the protective effect of EGFR-AS1 silencing.
conclusionsEGFR-AS1 is a clinical auxiliary biomarker for GDM diagnosis and prediction. It aggravates HPVECs injury via EGFR-AS1/miR-142-5p/ROCK2 axis, which impairs placental function and triggers APOs, providing a new target for GDM intervention.
Indexed as
Identifiers
42340571What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.